Skip to main content

Table 3 GRADE Approach for RCTs with low risk of bias

From: Tranexamic acid is associated with reduced mortality, hemorrhagic expansion, and vascular occlusive events in traumatic brain injury – meta-analysis of randomized controlled trials

Certainty assessment

№ of patients

Effect

Certainty

№ of studies

Study design

Risk of bias

Inconsistency

Indirectness

Imprecision

Other considerations

Tranexamic Acid

placebo

Relative (95% CI)

Absolute (95% CI)

Mortality

 5

randomised trials

not serious

not serious

not serious

not serious

none

2385/15179 (15.7%)

2575/15083 (17.1%)

RR 0.92 (0.87 to 0.97)

14 fewer per 1000 (from 22 fewer to 5 fewer)

HIGH

Hemorrhage Expansion

 4

randomised trials

not serious

not serious

not serious

not serious

none

106/471 (22.5%)

135/467 (28.9%)

RR 0.78 (0.63 to 0.97)

64 fewer per 1000 from 107 fewer to 9 fewer)

HIGH

Need for Neurosurgical Intervention

 4

randomised trials

not serious

not serious

not serious

not serious

none

1113/10566 (10.5%)

1125/10569 (10.6%)

RR 0.99 (0.89 to 1.12)

1 fewer per 1000 (from 12 fewer to 13 more)

HIGH

Unfavourable GOS

 3

randomised trials

not serious

not serious

not serious

serious a

none

137/455 (30.1%)

147/463 (31.7%)

RR 0.93 (0.72 to 1.21)

22 fewer per 1000 (from 89 fewer to 67 more)

MODERATE

Vascular Occlusive Events

 4

randomised trials

not serious

serious b

not serious

not serious

none

328/67281 (0.5%)

387/66981 (0.6%)

RR 0.85 (0.73 to 0.99)

1 fewer per 1000 (from 2 fewer to 0 fewer)

MODERATE

Vascular Occlusive Events - DVT

 4

randomised trials

not serious

not serious

not serious

serious a

none

67/16851 (0.4%)

82/16774 (0.5%)

RR 0.79(0.53 to 1.19)

1 fewer per 1000 (from 2 fewer to 1 more)

MODERATE

Vascular Occlusive Events - MI

 3

randomised trials

not serious

not serious

not serious

serious a

none

56/16731 (0.3%)

76/16656 (0.5%)

RR 0.75 (0.50 to 1.11)

1 fewer per 1000 (from 2 fewer to 1 more)

MODERATE

  1. CI Confidence interval, RR Risk ratio, TXA Tranexamic Acid
  2. Explanations
  3. a. Confidence intervals included potential for important harm or benefit and the risk ratio < 0.75
  4. b. Heterogeneity > 40%